REMSleep Holdings, Inc. has announced the full commercial launch of its DeltaWave nasal pillow system across all U.S. distribution channels, including durable medical equipment companies and institutional sales. This launch follows the completion of regulatory prerequisites, including expanded FDA 510(k) clearance secured on January 15 and Medicare PDAC coding approval for every product configuration on January 21. The company has been building infrastructure for this launch over several months, activating enterprise ERP systems in December 2025, deploying a nationwide independent sales force across 48 states, and receiving product inventory. Early results from a soft launch with DME partners showed zero-return, repeat-order validation.
The expanded FDA clearance, documented under K253939, broadened DeltaWave's indicated use to BiPAP, institutional settings, hospitals, long-term care facilities, and sleep labs. The DeltaWave system features patented Direct Airflow Technology designed to reduce the pressure and airflow sensation patients experience at the nasal interface. This engineering approach aims to address therapy compliance problems, as patients who feel less pressure effects tend to stay on therapy longer. The full commercial portfolio includes a Starter Kit with all three nasal pillow sizes, Single Pillow Systems for resupply, a Nasal Interface without headgear, and a complete accessories suite.
With PDAC coding approvals covering every configuration, DME providers can now bill Medicare and private insurers for DeltaWave products. This development is significant in the sleep medicine market where CPAP compliance remains a persistent challenge, with 30 to 50 percent of patients abandoning therapy within the first year, often due to mask discomfort. DeltaWave positions itself as a rescue mask alternative when standard formulary options aren't working for patients. The expanded clearance also opens institutional channels previously inaccessible under the original 510(k) language, including hospitals, long-term care facilities, rehabilitation centers, and sleep labs. These channels introduce solutions to patients at the beginning of therapy, potentially creating downstream revenue opportunities for DME partners as patients continue reordering products they become comfortable using.
Thomas Wood, CEO and Founder of REMSleep, stated that after years of personally funding the product through FDA processes, patents, clinical testing, and operational hurdles, the company is now launching at scale. He emphasized that DeltaWave was designed from day one to provide patients with a more comfortable breathing experience to improve therapy adherence. The product is available through REMSleep's direct sales channels, and more information can be found at https://www.remsleep.com.
